SMARCA2 and SMARCA4 expression in epithelioid pleural mesothelioma: association with inflammatory microenvironment
Journal of Current Hematology & Oncology Research · 25.02.2026 · 4 (1) · 18-24
DOI: 10.51271/jchor-0076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Current Hematology & Oncology Research, online erschienen am 25.02.2026. Verfasst von Neslihan Fener.
Abstract (Originalsprache)
Aims
To investigate the frequency of SMARCA2 and SMARCA4 loss in epithelioid pleural mesothelioma (PM) and to evaluate their clinicopathological correlates, with particular attention to the inflammatory tumor microenvironment.
Methods
This retrospective study included 64 patients who underwent surgery for epithelioid PM between January 2007 and October 2019. Cases with biphasic histology, unavailable clinical data or tissue blocks, and early postoperative mortality were excluded. Clinicopathological parameters (age, sex, stage, histologic pattern, necrosis, inflammation) were reviewed. Immunohistochemistry for SMARCA2 and SMARCA4 was performed on tissue microarrays using anti-SMARCA4 (clone EPNCIR111A, 1:100) and anti-SMARCA2 (clone D9E8B, 1:100). Loss of expression was defined as complete absence of nuclear staining in tumor cells in the presence of an internal stromal positive control. Statistical analyses were conducted using R (version 3.5.1). Associations between categorical variables were assessed using chi-square or Fisher’s exact tests; continuous variables were compared using Student’s t-test or one-way ANOVA.
Results
The cohort comprised 51 men (79%) and 13 women (21%), with a mean age of 57.1 ± 12 years (range, 30–91). Fifty-three patients (82.8%) underwent decortication and 11 (17.2%) extrapleural pneumonectomy. Most tumors were stage I (n = 60, 94%), with 4 (6%) at stage II. Histologic patterns were tubulopapillary (n = 33, 50%), trabecular (n = 2, 3%), adenomatoid (n = 11, 18%), solid (n = 3, 6%), and micropapillary (n = 15, 23%). Inflammation was mild in 58 cases (91%) and severe in 6 (9%); necrosis was present in 8 cases (12.6%). Loss of SMARCA2 and SMARCA4 expression was detected in 4 patients each (6% for both markers). SMARCA2 loss was significantly associated with severe inflammation (p = 0.02), whereas no significant relationships were observed between SMARCA4 loss and age, sex, stage, histologic pattern, necrosis, or inflammation.
Conclusion
SMARCA2 and SMARCA4 loss are uncommon events in epithelioid PM. However, SMARCA2 deficiency is associated with a pronounced lymphocytic/inflammatory response, suggesting that SWI/SNF complex alterations may contribute to an immunogenic tumor microenvironment and could have potential biomarker or therapeutic relevance.
Zitieren
APA
Fener, N. (2026). SMARCA2 and SMARCA4 expression in epithelioid pleural mesothelioma: association with inflammatory microenvironment. Journal of Current Hematology & Oncology Research, 4(1), 18-24. https://doi.org/10.51271/jchor-0076
Vancouver
Fener N. SMARCA2 and SMARCA4 expression in epithelioid pleural mesothelioma: association with inflammatory microenvironment. Journal of Current Hematology & Oncology Research. 2026;4(1):18-24. doi:10.51271/jchor-0076
BibTeX
@article{Fener2026,
author = {Fener, Neslihan},
title = {SMARCA2 and SMARCA4 expression in epithelioid pleural mesothelioma: association with inflammatory microenvironment},
journal = {Journal of Current Hematology & Oncology Research},
year = {2026},
volume = {4},
number = {1},
pages = {18--24},
doi = {10.51271/jchor-0076}
}
EUVIMED